Polypill for Cardiovascular Disease Prevention in an Underserved Population

Area of Science:

• Cardiovascular Disease Prevention
• Public Health Interventions
• Pharmacology

Background:

• High rates of cardiovascular disease (CVD) exist in low socioeconomic status and nonwhite populations in the US.
• Polypills, combining CVD-preventive medications, may benefit these groups.
• Limited data exist on polypill use in underserved US communities with low adherence to standard care.

Purpose of the Study:

• To evaluate the effectiveness of a polypill-based strategy for CVD risk reduction.
• To assess changes in blood pressure and LDL cholesterol in a socioeconomically vulnerable minority population.

Main Methods:

• A randomized controlled trial was conducted at a community health center in Alabama.
• Participants received either a polypill (atorvastatin, amlodipine, losartan, hydrochlorothiazide) or usual care.
• Primary outcomes measured were changes in systolic blood pressure and LDL cholesterol at 12 months.

Main Results:

• The trial enrolled 303 adults, predominantly Black individuals from low-income households.
• Adherence to the polypill regimen was 86% at 12 months.
• The polypill group showed significantly greater reductions in systolic blood pressure (-7 mm Hg) and LDL cholesterol (-11 mg/dL) compared to usual care.

Conclusions:

• A polypill strategy effectively reduced systolic blood pressure and LDL cholesterol in a socioeconomically vulnerable minority population.
• This approach offers a promising strategy for CVD prevention in underserved communities.
• The study highlights the potential of polypills to improve adherence and health outcomes.